Search Results - "Tap, William"

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought by Klein, Mary E., Kovatcheva, Marta, Davis, Lara E., Tap, William D., Koff, Andrew

“…CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone…”
Get full text

Multidisciplinary care in tenosynovial giant cell tumours by Tap, William D

“…Tenosynovial giant cell tumour is a rare neoplastic condition of the joint that generally affects patients younger than 40 years.1 It is not a malignancy per…”
Get full text

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials by D'Angelo, Sandra P, Mahoney, Michelle R, Van Tine, Brian A, Atkins, James, Milhem, Mohammed M, Jahagirdar, Balkrishna N, Antonescu, Cristina R, Horvath, Elise, Tap, William D, Schwartz, Gary K, Streicher, Howard

“…Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We…”
Get full text

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial by Tap, William D, Dr, Jones, Robin L, MD, Van Tine, Brian A, MD, Chmielowski, Bartosz, MD, Elias, Anthony D, Prof, Adkins, Douglas, Prof, Agulnik, Mark, MD, Cooney, Matthew M, MD, Livingston, Michael B, MD, Pennock, Gregory, MD, Hameed, Meera R, MD, Shah, Gaurav D, MD, Qin, Amy, PhD, Shahir, Ashwin, MD, Cronier, Damien M, PhD, Ilaria, Robert, MD, Conti, Ilaria, MD, Cosaert, Jan, MD, Schwartz, Gary K, Prof

“…Summary Background Treatment with doxorubicin is a present standard of care for patients with metastatic soft-tissue sarcoma and median overall survival for…”
Get full text

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment by D’Angelo, Sandra P., MD, Shoushtari, Alexander N., MD, Agaram, Narasimhan P., MD, Kuk, Deborah, Qin, Li-Xuan, PhD, Carvajal, Richard D., MD, Dickson, Mark A., MD, Gounder, Mrinal, MD, Keohan, Mary Louise, MD, Schwartz, Gary K., MD, Tap, William D., MD

“…Summary The prognostic and predictive implications of programmed death-ligand 1 (PD-L1) is unknown in sarcoma. We sought to examine the immune milieu in…”
Get full text

Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma by Chudgar, Neel P., MD, Brennan, Murray F., MD, Munhoz, Rodrigo R., MD, Bucciarelli, Peter R., MD, Tan, Kay See, PhD, D'Angelo, Sandra P., MD, Bains, Manjit S., MD, Bott, Matthew, MD, Huang, James, MD, Park, Bernard J., MD, Rusch, Valerie W., MD, Adusumilli, Prasad S., MD, Tap, William D., MD, Singer, Samuel, MD, Jones, David R., MD

“…Abstract Objective Soft-tissue sarcoma is a heterogeneous disease that frequently includes the development of pulmonary metastases. The purpose of this study…”
Get full text

Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets by Rosenbaum, Evan, Jadeja, Bhumika, Xu, Bin, Zhang, Lei, Agaram, Narasimhan P., Travis, William, Singer, Samuel, Tap, William D., Antonescu, Cristina R.

“…Epithelioid hemangioendothelioma is a low-grade malignant vascular tumor with an intermediate clinical behavior between benign hemangiomas and high-grade…”
Get full text

Locally Aggressive Connective Tissue Tumors by Gounder, Mrinal M, Thomas, David M, Tap, William D

“…In this review, we highlight the complexities of the natural history, biology, and clinical management of three intermediate connective tissue tumors: desmoid…”
Get full text

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation by Gounder, Mrinal M, Solit, David B, Tap, William D

“…In a patient with treatment-refractory follicular lymphoma, a biopsy showed a histiocytic sarcoma related to the lymphoma but with an activating mutation in…”
Get full text

The epigenomics of sarcoma by Nacev, Benjamin A., Jones, Kevin B., Intlekofer, Andrew M., Yu, Jamie S. E., Allis, C. David, Tap, William D., Ladanyi, Marc, Nielsen, Torsten O.

“…Epigenetic regulation is critical to physiological control of development, cell fate, cell proliferation, genomic integrity and, fundamentally, transcriptional…”
Get full text

GeDDiS: insight into frontline therapy in soft tissue sarcoma by Tap, William D

“…The combination of gemcitabine and docetaxel gained favour in the USA after efficacy was noted in uterine leiomyosarcoma1,2 and later in sarcoma, generally…”
Get full text

ATRX guards against aberrant differentiation in mesenchymal progenitor cells by Fang, Yan, Barrows, Douglas, Dabas, Yakshi, Carroll, Thomas S, Singer, Sam, Tap, William D, Nacev, Benjamin A

“…Alterations in the tumor suppressor ATRX are recurrently observed in mesenchymal neoplasms. ATRX has multiple epigenetic functions including heterochromatin…”
Get full text

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors by Lee, William, Teckie, Sewit, Wiesner, Thomas, Ran, Leili, Prieto Granada, Carlos N, Lin, Mingyan, Zhu, Sinan, Cao, Zhen, Liang, Yupu, Sboner, Andrea, Tap, William D, Fletcher, Jonathan A, Huberman, Kety H, Qin, Li-Xuan, Viale, Agnes, Singer, Samuel, Zheng, Deyou, Berger, Michael F, Chen, Yu, Antonescu, Cristina R, Chi, Ping

“…Ping Chi and colleagues identify recurrent inactivating mutations in the PRC2 core components EED and SUZ12 in malignant peripheral nerve sheath tumors. They…”
Get full text

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial by Tap, William D, Gelderblom, Hans, Palmerini, Emanuela, Desai, Jayesh, Bauer, Sebastian, Blay, Jean-Yves, Alcindor, Thierry, Ganjoo, Kristen, Martín-Broto, Javier, Ryan, Christopher W, Thomas, David M, Peterfy, Charles, Healey, John H, van de Sande, Michiel, Gelhorn, Heather L, Shuster, Dale E, Wang, Qiang, Yver, Antoine, Hsu, Henry H, Lin, Paul S, Tong-Starksen, Sandra, Stacchiotti, Silvia, Wagner, Andrew J

“…Tenosynovial giant cell tumour (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no…”
Get full text

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial by Heinrich, Michael C, Jones, Robin L, von Mehren, Margaret, Schöffski, Patrick, Serrano, César, Kang, Yoon-Koo, Cassier, Philippe A, Mir, Olivier, Eskens, Ferry, Tap, William D, Rutkowski, Piotr, Chawla, Sant P, Trent, Jonathan, Tugnait, Meera, Evans, Erica K, Lauz, Tamieka, Zhou, Teresa, Roche, Maria, Wolf, Beni B, Bauer, Sebastian, George, Suzanne

“…Targeting of KIT and PDGFRA with imatinib revolutionised treatment in gastrointestinal stromal tumour; however, PDGFRA Asp842Val (D842V)-mutated…”
Get full text

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial by Tap, William D, Wagner, Andrew J, Schöffski, Patrick, Martin-Broto, Javier, Krarup-Hansen, Anders, Ganjoo, Kristen N, Yen, Chueh-Chuan, Abdul Razak, Albiruni R, Spira, Alexander, Kawai, Akira, Le Cesne, Axel, Van Tine, Brian A, Naito, Yoichi, Park, Se Hoon, Fedenko, Alexander, Pápai, Zsuzsanna, Soldatenkova, Victoria, Shahir, Ashwin, Mo, Gary, Wright, Jennifer, Jones, Robin L

“…IMPORTANCE: Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival…”
Get full text

Towards a new era in the treatment of Ewing sarcoma by Slotkin, Emily K, Tap, William D

“…Additionally, the studied population in EE2012 is notable for the proportion of patients (78 [24%] in group 1 and 71 [22%] in group 2) who received surgical…”
Get full text

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma by DICKSON, Mark A, TAP, William D, USTOYEV, Yelena, CRAGO, Aimee M, SINGER, Samuel, SCHWARTZ, Gary K, KEOHAN, Mary Louise, D'ANGELO, Sandra P, GOUNDER, Mrinal M, ANTONESCU, Cristina R, LANDA, Jonathan, QIN, Li-Xuan, RATHBONE, Dustin D, CONDY, Mercedes M

“…CDK4 is amplified in > 90% of well-differentiated (WDLS) and dedifferentiated liposarcomas (DDLS). The selective cyclin-dependent kinase 4 (CDK4)/CDK6…”
Get full text

NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma by Chiang, Sarah, Cotzia, Paolo, Hyman, David M, Drilon, Alexander, Tap, William D, Zhang, Lei, Hechtman, Jaclyn F, Frosina, Denise, Jungbluth, Achim A, Murali, Rajmohan, Park, Kay J, Soslow, Robert A, Oliva, Esther, Iafrate, A John, Benayed, Ryma, Ladanyi, Marc, Antonescu, Cristina R

“…Tropomyosin receptor kinase (Trk) inhibitors have shown high response rates in patients with tumors harboring NTRK fusions. We identified 4 NTRK…”
Get full text

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas by Anderson, Jennifer L, Park, Ann, Akiyama, Ryan, Tap, William D, Denny, Christopher T, Federman, Noah

“…Pediatric bone and soft tissue sarcomas often display increased Akt phosphorylation through up regulation of insulin-like growth factor (IGF1) signaling…”
Get full text